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Paf-acether (pat') is a potent mediator of inflammatory diseases and septic shock. Using normal-phase HPLC, a paf-like 
activity was found in culture supernatants from E. coli. Prokaryotic pafexhibited the same biological and physico-chemi- 
cal properties as eukaryotic ells and synthetic paf. Further, reverse-phase HPLC indicates that paf generated by bacteria 
is predominantly of the bexadecyl and octadecyl species. When cultures were supplemented with lyso-paf, a dramatic 
increase in paf production was observed. The purity and molecular structure of bacterial paf were further characterized 
by mass spectral analysis. These results could be of importance considering the pathogenetic role of enterobacteria. Fur- 
ther, it appears that the competence to form and release paf is an early phylogenetic development. 
Platelet activating factor-acether: Mass spectral analysis; (Escherichia coli) 
1. INTRODUCTION 
Paf-acether (paf: 1-O-alkyl-2-acetyl-sn-glycero L 
3-phosphocholine [1,2], formerly platelet-activat- 
ing factor) is a phospholipid mediator initially 
described as a product of IgE-sensitized rabbit 
basophils [3]. It is now known to be rapidly syn-" 
thesized by a variety of cells after appropriate 
stimulation [4,5]. The growing importance of this 
mediator in inflammatory processes [6], along with 
the striking similarities of its properties in many 
eukaryotic species, suggested tous that paf may be 
a molecule that has been conserved through evolu- 
tion. We show here that E. coli contains paf and 
can acetylate xogenous lyso-paf to generate and 
release large amounts of the bioactive compound. 
This work reports for the first time the release of 
paf by E. coli, a result that could be of some im- 
portance since (i) the potent proinflammatory 
mediator paf could contribute to the pathology 
produced by enterobacteria, and (ii) the existence 
of paf in a prokaryote suggests hat it is an ancient 
and functionally conserved molecule, possibly with 
a wider role than that of a proinflammatory 
autacoid. 
2. MATERIALS AND METHODS 
2.1. Bacterial culture conditions 
Four different strains of bacteria were grown aerobically at 
37°C in a rich complex medium (ML) [7], supplemented with 
0.25% lipid-free bovine serum albumin (Sigma, St. Louis, MO, 
USA). After 16 h, bacteria from a standard culture (10 ml, 1 x 
109 cells) were harvested by centrifugation (600 × g, 15 min). In 
most of the experiments bacteria were supplemented at the 
beginning of the culture with lyso-paf (l-O-alkyl- 
glycero-3-phosphocholine; Bachem, Bubendorf, Switzerland). 
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2.2. HPLC on lipid fractions 
Lipids were extracted from both supernatants and cell pellets 
according to Bligh and Dyer methods [8]. The dried residue was 
dissolved in 500ul of HPLC solvent (dichloromethane/ 
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methanol/water, 60:50:5). Samples were applied to a Micro- 
porasil column 3.9 mm 1D x 300 mm length (Waters Asso- 
ciates, Milford, MA), which was then eluted at a flow rate of 
1 ml/min. 1 ml fractions were dried and resuspended in 50 #1 of 
6007o ethanol and then assayed for platelet-aggregating activity. 
2.3. Paf assay 
Washed rabbit platelets were prepared as in [9]. Aspirinated 
platelets (1.6 x l08) in Tyrode's (300#1) containing 2.507o 
gelatin and the ADP scavenger mixture, creatine phosphate 
(1 mM)/creatine phosphokinase (10 U/ml) were stirred in an 
aggregometer (lcare, Marseille, France). Aggregating activity of 
the samples was measured over the linear portion of the calibra- 
tion curve obtained with 5-50 pg synthetic paf (Bachem). 
2.4. Mass spectral analysis 
The HPLC fractions were introduced into an Extrel 400-2 
quadrupole mass pectrometer via a Vestec thermospray inter- 
face (Vestec, Houston, TX, USA) as described previously [101. 
Vaporisation and ionisation were achieved by heating the 
capillary vaporiser and also by applying an electron-emitting 
filament current (0.2 A). Without his auxiliary ionising source, 
sufficient ionisation did not occur since a mobile phase xtreme- 
ly high in organic ontent was required to dissolve and elute the 
phospholipids. Excess olvent was pumped away through a 
vacuum line via a dry ice/isopropyl alcohol cold trap. The 
vaporiser tip temperature was maintained at 145-148°C and the 
source temperature at 300°C. All data were acquired with an 
Extrel EL-1000 data system. 
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Table 1 
Formation of paf-acether in E. coli strains 
Strains Genotype paf  a 
POP 1021 F-, metA, trp 132 _+ 48 
PAP 271 F-, metA, bio, thyA, endA 138 + 90 
PAP 274 F-, bio, thyA, pldA 60 + 40 
0111 :B4 NA b 200 + 120 
a In pg paf for 1 × 10 9 bacteria (mean _+ SE of 7 experiments) 
b NA, not available 
(a gift f rom Dr Nagawa, Takeda Chemical Indust. 
Ltd, Osaka, Japan) and BN 52021 (obtained f rom 
IHB, Le Plessis-Robinson, France), inhibited 
platelet aggregation induced by submaximal con- 
centrat ion of  both E. coli paf and synthetic paf 
[12]. (iii) The activity was eluted f rom reverse- 
phase HPLC at the same retention time as syn- 
thetic C16 and C18 paf (for about 50°7o of  the ac- 
tivity each) (not shown). 
We next investigated whether paf release could 
be l imited by the amounts of  its precursor, lyso- 
paf. The latter compound,  totally devoid of  ag- 
3. RESULTS 
As shown in table 1, when lipids extracted f rom 
bacteria cultured for 16 h were submitted to nor- 
mal phase HPLC,  some eff luent fractions contain- 
ed an activity that induced aggregation of  washed 
rabbit platelets unresponsive to ADP and 
arachidonic acid. The active fractions were eluted 
f rom the column with a retention time identical to 
that of  authentic paf whereas no paf  activity was 
detected elsewhere in the chromatogram. In the 
major i ty of  individual experiments (n = 28), more 
than 90°70 of this activity was recovered in the 
culture media, the rest remaining cell-associated. 
In the absence of  bacteria, no paf  was detected in 
either culture med ia .  
Apart  from its chromatographic  behaviour,  the 
platelet-aggregating substance appeared un- 
distinguishable from authentic paf: (i) the ag- 
gregating activity found in the extract was totally 
inactivated by treatment with phosphol ipase Az 
but not with lipase At [11]. (ii) The three an- 
tagonists of  the paf putative receptor L 652,731 
(generously provided by Dr J. Chabala, Merck 
Sharp and Dohme, Rahway, N J, USA),  CV-3988 
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Fig. 1. Effects of exogenous lyso paf on paf formation. E. coli 
POP 1021 was grown in the absence or presence of varying 
amounts of synthetic C16 lyso-paf. After 16 h, lipids were 
extracted and paf content assayed as indicated in section 2. 
Results are expressed inng paf/l x 10 9 bacteria (mean + SE of 
4 experiments). 
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Fig.2. Separation and detection of molecular species of 
bacterial paf using coupled HPLC and thermospray mass 
spectrometry. A pool of bacterial paf, obtained following 
supplementation with 0.5 mM C16 lyso-paf, and eluted from 
direct phase HPLC was analysed by HPLC coupled 
thermospray mass pectrometry. Peaks denoted A and B in the 
spectra represent fragments derived from phosphocboline and 
diglyceride ions, respectively. 
gregating property, is the immediate paf precursor 
as it is a substrate for an acetyltransferase; it is also 
a paf catabolite after acetylhydrolase attack [13]. 
As shown in fig.l, exogenous C16 lyso-paf 
markedly enhanced in a dose-dependent manner 
the synthesis and release of paf by E. coli K12. As 
compared to medium alone a 10- to 420-fold in- 
crease in paf production was observed when 
bacteria were cultured in the presence of lyso-paf 
from 10/zM to 1 mM, whereas lyso-paf from 
0.1/zM to 10/zM was not effective. Of note, lyso- 
paf (up to 1 raM) had no effect on cell growth or 
viability. In a further attempt to characterize 
bacterial paf, the active fraction obtained follow- 
ing supplementation with 0.5 mM C16 lyso-paf 
and eluted from the normal-phase HPLC was 
analyzed using thermospray mass spectrometry. 
The mass fragmentation pattern of the extract is 
depicted in fig.2. The major fragment peak 
resulting from the head group loss (m/z 341) 
represents the diglyceride ion containing the 16:0 
fatty alkyl moiety. Ions from the choline head 
group (m/z 142 and 184) were also present. 
4. DISCUSSION 
In the present work, large amounts of paf (up to 
80 ng) were produced by a relatively low number 
of bacteria (1 × 109), indicating that biological ac- 
tivity of high physiological and pathological 
significance can be expressed in the microorganism 
environment. Identity of the prokaryotic molecule 
with authentic paf is based on the stringent func- 
tional and biochemical criteria detailed above in- 
cluding two types of HPLC and mass 
spectrometric analysis. It should be pointed out, 
however, that the amount of paf formed by 
bacteria in the absence of exogenous lyso-paf was 
insufficient for structural analysis using the latter 
method: 
Since ether-linked and choline-substituted 
phospholipids have not yet been reported in E. 
coli, what is the mechanism by which E. coli can 
synthesize de novo the alkyl-ether, choline- 
containing mediator? The simplest interpretation 
of these findings is that paf results from the 
bioconversion of paf precursors present in culture 
media, indeed 1 nM lyso-paf was detected in 
culture media. An alternative view is that E. coli 
itself contains small amounts of 1-O-alkyl- 
glycero-3-phosphocholine u detectable using con- 
ventional means yet sufficient o support paf syn- 
thesis. In this regard, our bioassay is able to detect 
sub-picogram amounts of active ether-linked 
phospholipids, thus several orders of magnitude 
more sensitive than conventional physico-chemical 
methods. Clearly, further studies will be required 
to allow definitive conclusions on the endogenous 
vs exogenous origin of the alkyl-ether 
phosphatidylcholine backbone of paf found in un- 
supplemented bacteria. Nonetheless, upplementa- 
tion with the lyso precursor of paf led to a major 
increment in paf production, indicating most likely 
the existence in E. coli of an acyltransferase activi- 
ty as previously reported for long chain fatty acids 
[14]. There is also evidence to suggest that the lyso- 
paf resulting from the degradation of most 
eukaryotic cell membranes is abundant in the 
natural environment of the bacteria, thus pro- 
viding the 'raw material' to be acetylated into paf. 
At the present time, the function of paf in E. coli 
is not known. For example, it could be implicated 
in bacteria-related pathogenic events. Indeed, the 
role of paf has been suspected in necrotizing 
enterocolitis [15], gastric ulceration [16] and 
Gram-negative septic shock [17]. 
Therefore, the existence of bacterial paf either 
alone or associated with bacterial endotoxin could 
15 
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support  the concept of  the local and/or  general 
release of  this mediator  f rom bacterial  and/or  host 
sources init iating or ampl i fy ing gastro- intest inal  
damages or septic shock. The release of  lyso-paf  
fol lowing phosphol ipase A2 activation and/or  cell 
damage during the initial local in jury could trigger 
an increment of  paf  synthesis by saprophyte or 
pathogenet ic bacteria, thus producing an auto-  
ampl i fy ing injury. 
Final ly,  the strict similarity of  prokaryot ic  and 
eukaryot ic  paf,  considered along with the 
phylogenic posit ion of  the enterobacter ia,  suggests 
a more fundamental  role for paf  than the now 
classical ones in allergy and in f lammat ion and 
opens a new area for speculation. For  instance, is 
pa l  involved in the physiology of  the bacter ia 
itself? Was this mediator ,  a major  effector of  cell- 
cell communicat ion,  also regulating interactions 
between bacter ia and, later, between bacter ia and 
more complex organisms. Bacterial mutants-  
lacking paf  could be helpful probes in approaching 
these issues. 
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